Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience

Giulio Rizzetto, Federico Diotallevi, Anna Campanati, Giulia Radi, Tommaso Bianchelli, Elisa Molinelli, Sara Mazzanti, Annamaria Offidani, Giulio Rizzetto, Federico Diotallevi, Anna Campanati, Giulia Radi, Tommaso Bianchelli, Elisa Molinelli, Sara Mazzanti, Annamaria Offidani

Abstract

Telogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies, and febrile states. We report three cases of TE occurred after severe Sars-Cov-2 infection and provide our clinical management, according to Sars-Cov-2 hygiene measures. Only one case report has been found in the literature associating anagen effluvium during severe Sars-Cov-2 infection. Other studies reported the exacerbation of a preexisting TE, correlated to the stress of lockdown. In our cases, patients never had a TE diagnosis before and did not report previous evident hair loss. TE can be associated with post severe Sars-Cov-2 infection. From our revision of the literature, this is the first case-series describing TE in post severe Sars-Cov-2 patients. Further studies are needed to evaluate the relationship between TE and Sars-Cov-2 infection.

Keywords: alopecia; hair disorders; infection-bacterial/fungal/viral; therapy-systemic.

Conflict of interest statement

The authors declare no conflicts of interests.

© 2020 Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
A, widespread reduction in hair density. B, Trichoscopy revealed a reduction in hair density and some empty follicles, with the integrity of the stem and the absence of miniaturized hair
FIGURE 2
FIGURE 2
A, Hair thinning and reduced central hair density. B, Trichoscopy showed a mild reduction in hair density without any other pathological findings
FIGURE 3
FIGURE 3
A, Diffuse reduced hair density without regression to the temporal regions. B, Trichoscopy showed a mild reduction in hair density with some with some hair of reduced thickness

References

    1. Trueb RM. Diffuse hair loss. In: Blume‐Peytavi U, Tosti A, Whiting DA, Trueb R, eds. Hair Growth and Disorders. 1st ed. Berlin: Springer; 2008:259‐272.
    1. Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01‐WE03.
    1. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2:189.
    1. Torres F, Tosti A. Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. Semin Cutan Med Surg. 2015;34(2):67‐71.
    1. Shanshal M. COVID‐19 related anagen effluvium [published online ahead of print, 2020 Jul 16]. J Dermatolog Treat. 2020;1‐2. 10.1080/09546634.2020.1792400.
    1. Guarrera M, Cardo PP, Rebora A. Assessing the reliability of the modified wash test. G Ital Dermatol Venereol. 2011;146(4):289‐294.
    1. Chu C‐B, Yang C‐C. Dengue‐associated telogen effluvium: a report of 14 patients. Dermatologica Sinica. 2017;35(3):124‐126.
    1. Bernstein GM, Crollick JS, Hassett JM Jr. Postfebrile telogen effluvium in critically ill patients. Crit Care Med. 1988;16:98‐99.
    1. Hazen HH. Postinfluenzal alopecia. JAMA. 1919;72:1452.
    1. Savil A. The Hair and Scalp – A Clinical Study. 4th ed. London: E. Arnold & Co.; 1952:85.
    1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the cytokine storm' in COVID‐19. J Infection. 2020;80(6):607‐613. 10.1016/j.jinf.2020.03.037.
    1. Garg S, Garg M, Prabhakar N, Malhotra P, Agarwal R. Unraveling the mystery of Covid‐19 cytokine storm: from skin to organ systems. Dermatol Ther. 2020;e13859.
    1. Diotallevi F, Campanati A, Bianchelli T, et al. Skin involvement in SARS‐CoV‐2 infection: case series. J Med Virol. 2020;92:2332‐2334. 10.1002/jmv.26012.
    1. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129(3):356‐363.
    1. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa‐2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):395‐407.
    1. Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature. Drugs Real World Outcomes. 2016;3(1):1‐6.
    1. Wang YY, Po HL. Enoxaparin‐induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Thera. 2006;31(5):513‐517.
    1. Borrás‐Blasco J, Belda A, Rosique‐Robles D, Casterá E, Abad J, Amorós‐Quiles I. Hair loss induced by lopinavir‐ritonavir. Pharmacotherapy. 2007;27(8):1215‐1218.
    1. Chrysos G, Mikros S, Kokkoris S, Pastelli A, Kontochristopoulos G. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. J Drugs Dermatol. 2007;6(7):742‐743.
    1. Vidon C, Bossert M, Lohse‐Walliser A, Godfrin‐Valnet M, Balblanc JC, Wendling D. Hair‐cycle changes in two patients taking tocilizumab. Joint Bone Spine. 2014;81(1):100‐101.
    1. Mysore V, Parthasaradhi A, Kharkar RD, et al. Expert consensus on the management of Telogen effluvium in India. Int J Trichology. 2019;11(3):107‐112.
    1. Bomhof G, Mutsaers PGNJ, Leebeek FWG, et al. COVID‐19‐associated immune thrombocytopenia. Br J Haematol. 2020;190(2):e61‐e64.
    1. Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7:1‐10.
    1. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186‐194.
    1. Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019‐nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020;34:e213‐e214.
    1. Campanati A, Brisigotti V, Diotallevi F, et al. Active implications for dermatologists in “SARS‐CoV‐2 ERA”: personal experience and review of literature. J Eur Acad Dermatol Venereol. 2020;34:1626‐1632.
    1. Diotallevi F, Radi G, Campanati A, et al. Time to restart: protocol of resumption of activities of a dermatological clinic of a level ii hospital in the COVID‐19 era. Int J Dermatol. [Epub ahead of print].
    1. Radi G, Simonetti O, Diotallevi F, et al. How can I take care of you? The dermatologist meets patients' needs during the COVID‐19 pandemic. Dermatol Ther. 2020;e13740 [published online ahead of print, 2020 Jun 1].
    1. Turkmen D, Altunisik N, Sener S, Colak C. Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire. Dermatol Ther. 2020;e13923 [published online ahead of print, 2020 Jun 28].
    1. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID‐19 emergency: psychological implications. Dermatol Ther. 2020;e13648 [published online ahead of print, may 22, 2020].

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe